GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valeo Pharma Inc (TSX:VPH) » Definitions » EV-to-FCF

Valeo Pharma (TSX:VPH) EV-to-FCF : -8.33 (As of Jun. 19, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Valeo Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Valeo Pharma's Enterprise Value is C$69.97 Mil. Valeo Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 was C$-8.40 Mil. Therefore, Valeo Pharma's EV-to-FCF for today is -8.33.

The historical rank and industry rank for Valeo Pharma's EV-to-FCF or its related term are showing as below:

TSX:VPH' s EV-to-FCF Range Over the Past 10 Years
Min: -28.73   Med: -4.51   Max: -2.19
Current: -8.04

During the past 7 years, the highest EV-to-FCF of Valeo Pharma was -2.19. The lowest was -28.73. And the median was -4.51.

TSX:VPH's EV-to-FCF is ranked worse than
100% of 537 companies
in the Drug Manufacturers industry
Industry Median: 22.8 vs TSX:VPH: -8.04

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-19), Valeo Pharma's stock price is C$0.14. Valeo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was C$-0.330. Therefore, Valeo Pharma's PE Ratio for today is At Loss.


Valeo Pharma EV-to-FCF Historical Data

The historical data trend for Valeo Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valeo Pharma EV-to-FCF Chart

Valeo Pharma Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
EV-to-FCF
Get a 7-Day Free Trial -4.91 -7.42 -4.45 -2.61 -3.39

Valeo Pharma Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.74 -2.99 -4.28 -3.39 -10.21

Competitive Comparison of Valeo Pharma's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Valeo Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valeo Pharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valeo Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Valeo Pharma's EV-to-FCF falls into.



Valeo Pharma EV-to-FCF Calculation

Valeo Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=69.973/-8.399
=-8.33

Valeo Pharma's current Enterprise Value is C$69.97 Mil.
Valeo Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-8.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valeo Pharma  (TSX:VPH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Valeo Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.14/-0.330
=At Loss

Valeo Pharma's share price for today is C$0.14.
Valeo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.330.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Valeo Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Valeo Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Valeo Pharma (TSX:VPH) Business Description

Traded in Other Exchanges
Address
16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.
Executives
Luc Mainville Senior Officer

Valeo Pharma (TSX:VPH) Headlines

No Headlines